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Abstract: Mucosal nasopharyngeal melanoma is a rare head and neck melanoma. 
Prognosis is poor (5-year overall survival rate of 10–30%) with high rates of 
metastases and local recurrence. Head and neck mucosal melanoma represents 
0.8–3.7% of all melanomas and 0.03% of all neoplasms; the most commonly 
involved sites are the nose, paranasal sinuses, oral cavity, pharynx, and larynx. 
A slight female predominance has been described and the median age of presenta-
tion is 64.3. Irritants and carcinogenic substances, such as tobacco smoke and 
formaldehyde, seem to be related to its development. A lack of specific clinical 
features often leads to a late diagnosis. At an early stage, clinical features can 
include epistaxis, obstruction, difficulty breathing, serous otitis media, and nasal 
discharge; subsequently, pain, facial distortion, proptosis, and diplopia pre-
dominate the clinical pictures. Masses are mostly polyploid, friable, and bloody. 
They  can be amelanotic or surrounded by black- or brown-pigmented dots. 
Nasopharyngeal melanoma resembles other common polypoid lesions; therefore, 
Nasopharyngeal Melanoma50
histology plays a pivotal role in confirming the diagnosis. Computed tomography, 
facial and total body scan, as well as magnetic resonance imaging are mandatory 
for a correct staging. Surgical treatment remains the gold standard. External or 
intranasal incision depends on tumor site and size. Sentinel lymph node biopsy is 
not usually performed. Neck dissection is indicated in cases of clinical and/or 
radiological positivity. Radiotherapy is mostly palliative, as radiotherapy lacks effi-
cacy for mucosal melanomas. The effectiveness of target therapy and/or immuno-
therapy is undergoing evaluation.
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INTRODUCTION
Melanocytes are normally present in the mucous membrane of nasal cavities and 
paranasal sinuses in about 20% of the population (1). The biology of extracutane-
ous melanoma differs from that of cutaneous melanomas. Indeed, several func-
tions of melanocytes, such as antimicrobial and immunological functions, have 
been recently reported. Furthermore, due to the involvement of anatomical sites 
such as oropharyngeal, anorectal, penile, and vulvar areas where specific viruses 
(e.g. human papillomavirus [HPV]) harbor, a role for melanocytes in viral patho-
genesis has been postulated.. Nasopharyngeal melanoma (NPM) is a rare type of 
head and neck mucosal melanoma (HNMM). Its prognosis is poor, with a 5-year 
overall survival rate of 10–30%, due to frequently delayed diagnosis, local recur-
rence, and high rates of metastases (2, 3). In this chapter, we illustrate and sum-
marize the main clinicopathologic features of NPM and the available therapeutic 
approaches.
EPIDEMIOLOGY
In the literature, few data about HNMM and NPM have been reported (2). The 
USA Cancer Database reports that about 1.3% of melanomas are mucosal, of 
which 55% are localized in the head and neck area (4, 5). Primary HNMM 
accounts only for 0.8–3.7% of all melanomas and 0.03% of all cancers (1). More 
specifically, HNMM accounts for 4% of head and neck melanomas and 4% of 
nasopharyngeal neoplasms (1, 2). It is estimated that the incidence of NPM is 
about 0.3/1,000,000 per year (1). The most commonly involved sites are the nose 
(80% of HNMM in sinonasal tract, especially occurring in lateral wall and sep-
tum), paranasal sinuses (involving mostly primary ethmoid and maxillary sinus), 
oral cavity, pharynx and larynx (2, 5). There is no real sex predominance, although 
females are slightly more commonly affected than males (52% vs. 48%) (6). The 
median age of presentation is 64.3 years (range: 50–80 years). However, cases of 
melanoma of the oral cavity have been reported in patients as young as 9 years 
old (7). NPM melanoma represents a greater percentage of all melanomas among 
Japanese compared to Caucasians. Specifically, 7.5% of all melanomas in the 
Japanese population arise in oral cavity, compared to ≤1% reported in the 
Caucasian population (5, 8).
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PATHOGENESIS
The role of irritants and carcinogenic compounds in the air, such as tobacco 
smoke and formaldehyde, in the development of NPM is not yet clear. Interestingly, 
it has been reported that hyper-production of melanocytes in the oral mucosa is 
associated with the use of cigarettes, leading to a greater prevalence of pigmented 
oral lesions (9–11). Several authors have reported that approximately 33% of 
mucosal melanomas of the oral cavity are preceded by oral melanosis (11). The 
significance of this finding is unclear and given the current levels of evidence 
melanosis should not be considered a pre-cancerous lesion. It is probable that 
most precursors of NPM originate from stem melanocytes that have acquired 
cytogenetic alternations of their oncogenes, tumor-suppressor genes, and DNA 
repair genes, performing a malignant phenotype (12). Otherwise, NPM can arise 
from mature melanocytes of the submucosa with cytogenetic alternations, due to 
several stimuli, including tobacco, trauma, and oxidative stress (12). Indeed, a 
reduction in melanin production can lead to an increase of oxidative stress metab-
olites, which cause DNA damage, promoting an initial cell transformation (13). 
Finally, the transformed melanocytes show specific alteration in the c-kit pathway, 
endothelin receptor type B/endothelin pathway, Wnt/β-catenin pathway, and in 
various cell-adhesion molecules (12, 14, 15).
GENETICS
Primary mucosal melanoma (PMM) is an extremely rare neoplasm and few studies 
have evaluated its genetic basis. Because of the anatomic locations involved and 
the paucity of early clinical clues, mucosal melanomas are often detected at 
advanced stages. Consequently, the prognosis is poorer than their cutaneous 
counterparts. NPM accounts for 55% of HNMM, and HNMM accounts for 55% of 
all mucosal melanomas (Table 1) (16). As reported by several authors (17–21), 
PMM shows distinctive characteristics in comparison with cutaneous melanoma 
(CM). It has been shown that primary sinonasal melanomas (SNMs) are character-
ized by several abnormalities that lead to diffuse activation of the PI3K/Akt and 
TABLE 1 Distribution of primary mucosal melanoma
PMM %
Head and neck 55
Anorectal 23.8
Female genital tract 18
Urinary tract 2.8
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RAS-MAPK pathways. As highlighted by Turri-Zanoni, alterations in these path-
ways are not associated with prognosis (17). Furthermore, it has been reported 
that early somatic events (KIT, NRAS, and BRAF mutations) are not frequent in 
primary SNMs (2, 4). Indeed, Turri-Zanoni et al. reported that BRAF mutations in 
exon 15 were not detected in 97% of melanomas (17). In addition, BRAFV600E 
mutations were not present in any of the cases (17). This finding has also been con-
firmed by Edwars et al., who detected no BRAF exon 15 mutation in 13 PMM (18). 
These findings corroborate the evidence that PMM shares no molecular features 
with CM. Furthermore, the lack of BRAF mutations in PMM suggests that the 
BRAF mutations in melanoma are influenced by the extent of sun exposure (16). 
In addition, this finding suggests that BRAF/MEK inhibitors are unlikely to be 
useful in the management of PMM (16). Conversely, NRAS mutations have been 
described in 22% of cases, involving codon 61 in 42.8%, codon 12 in 28.5%, and 
codon 13 in 28.5% (17). This mutation rate is similar to nonchronic sun-damage 
melanoma. Finally, KIT mutations were detected on either exon 11 or 18 in 12.5% 
of the cases (17). It has also been postulated that the expression of KIT in primary 
SNMs might indicate that the activation of PI3K/Akt and RAS-MAPK pathways 
might be dependent on ligand-dependent activation of this receptor (17). As 
reported by several authors, therapeutic c-KIT blockade could be useful in the 
treatment of PMM patients with activating KIT mutation (20–22).
Fluorescence in situ hybridization (FISH) analysis conducted on 32 primary 
SNMs showed gain of 6p25 (RREB1) in 100%, loss of 6q23 (MYB) in 76%, and 
gain of 11q13 (CCND1) in 65.6% (18). These findings are similar to the results 
reported in their cutaneous counterpart, which shows a high frequency of gain of 
6p25 and loss of 6q23. These findings show that some chromosomal aberration 
of CM could also be detected in SNM by FISH. Conversely, gain of 11q13 
(CCND1), which is described in >30% of CM, was not shown in SNM (17).
Edwards et al. described further peculiar chromosomic aberrations in SNM, 
including gains of 1q, 6p, and 8q (18). In particular, the authors detected a gain 
of 1q in all 14 analyzed specimens, and a gain of 6p in 93% of specimens (18). 
These results are intriguing, because 1q and 6p aberrations are usually detected in 
about 40–70% of other melanoma types, although it has been reported in several 
papers that PMM is characterized by distinctive genetic features in comparison 
with CM (18). Interestingly, the gains of 1q, 6p, and 8q in SNM occurred often in 
association with a loss of copy number or a normal copy number of the opposite 
chromosome arm, suggesting isochromosome formation (17, 18).
Turri-Zanoni et al. described loss of PTEN expression (<50% of positive cells) 
in 48.1% and a total absence of the protein in 33.3% of analyzed SNMs using 
immunohistochemistry (17). Furthermore, loss of p16INK4a in >50% of tumor 
cells was described in 55.2% of cases (17). The authors demonstrated that at least 
one tumor-suppressor gene was absent in 82.7% of cases, whereas loss of both 
p16 (CDKN2A gene) and PTEN was seen in 18.5% of the cases.
Data on the role of tumor-suppressor genes in PMM transformation and pro-
gression are inconclusive. It has been highlighted that loss of PTEN and activating 
mutations of PIK3CA play a pivotal role in the hyperactivation of PI3K-Akt path-
way in a wide variety of human neoplasms. As reported by Turri-Zanoni et al., the 
hyperactivation of PI3K-Akt pathway was found in 89.7% of SNM cases, not 
related to activating mutations of PIK3CA (17). Although these findings need fur-
ther investigation, they show that activation of PI3K-Akt might sustain the 
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development of SNM (22). Therefore, drugs that inhibit PI3K-Akt-mTOR path-
way could be useful when employed in SNM.
It has been speculated that the HPV could determine a higher genomic insta-
bility in PMM by supporting the degradation of the p53 protein (22, 23). However, 
Dahlgren et al. evaluated with PCR the presence of HPV DNA in 15 anal melano-
mas, 4 rectal melanomas, and 9 SNMs, and detected no HPV DNA in the analyzed 
samples (24). Therefore, the authors concluded that the 36 HPV subtypes tested 
did not play a pivotal role in the development of PMM.
CLINICAL FEATURES
The clinical presentation of NPM is nonspecific. Because of this and the anatomic 
area, median delay of 6–8 months in diagnosis has been estimated (3). Furthermore, 
the aggressiveness of this rare type of melanoma is also related to biological 
aspects. Indeed, especially in the initial stages, NPM is often asymptomatic. 
Primary clinical manifestations are usually obstruction of involved cavities and 
epistaxis. The most common symptoms of NPM, in decreasing order, are epi-
staxis, mass/obstructive symptoms, difficulty breathing, serous otitis media, pain, 
polyps, and nasal discharge (3, 9). In the most invasive stages, pain, facial distor-
tion, proptosis, and diplopia may be present (9, 25). In a case reported by Alves 
et al., a 64-year-old white, male patient had pain on the right side of his face and 
nose, associated with sporadic episodes of epistaxis and progressive ipsilateral 
nasal obstruction which had begun 1 year earlier (26). In another report by 
Bhartiya et al., a 51-year-old male presented with a 5-month history of nasal 
swelling, blockage, and occasional nasal bleeding, reporting a rapid increase in 
size of a swelling lesion on the left side of his nose (27). On examination, a large, 
swelling, fleshy, bluish-red, friable lesion was noticed on the left side of the nose, 
completely blocking the nasal passage (27). Finally, a report by Shradda et al. 
described the case of a 42-year-old female patient with swelling over the left side 
of her face, ipsilateral nasal blockage, and a visible brownish-colored mass in the 
left nasal cavity (28). The swelling, which was associated with severe throbbing 
type of pain, started over the lateral part of the nose on the left side, below the left 
eye, and rapidly increased in size, involving the eye and the left cheek with ulcer-
ation of the overlying skin (28).
Endoscopically, NPM could appear as a polyploid, friable, and bloody mass, 
with a homogeneous or heterogeneous surface (2). As reported by Alves et al., 
anterior rhinoscopy and fibre-optic-naso-laryngoscopy may show blackish-blue, 
pale yellow, or translucent polypoid masses (in the presence of amelanotic melanoma) 
(25). Besides, as reported by Lazzeri et al., NPM could also be detected as a gray-
ish stone-like material under the mucosa of a polypoid tissue (28). The primary 
lesion site is often difficult to detect because of the extension of the lesion at diag-
nosis (26). Furthermore, NPM is usually amelanotic and often mistaken for an 
ordinary nasal polyposis, delaying the diagnosis (2). Melanoma of nasal cavities 
and septum has a better prognosis than those of paranasal sinuses. This is proba-
bly due to the presence of clinical signs and symptoms, as well as better access, 
allowing for appropriate clinical examination, earlier diagnosis, and a more radi-
cal therapy. Regarding the pharyngeal involvement, in 66.6% of the cases, the first 
Nasopharyngeal Melanoma54
noticeable features are usually hoarseness, sore throat, irritation, dysphagia, and a 
cervical mass (25). The melanoma may also cause hemorrhage, difficulties in 
hearing and deglutition, voice changes, and breathing difficulties.
PATHOLOGY
NPM is often amelanotic, resembling a benign polypoid lesion. Therefore, histol-
ogy plays a pivotal role for a correct diagnosis (Figures 1 and 2). However, NPM 
can be also confused with other tumors, such as undifferentiated small blue cell 
tumors of the sinonasal tract, including olfactory neuroblastoma, sinonasal undif-
ferentiated neuroendocrine carcinoma, Ewing’s sarcoma, peripheral neuroecto-
dermal tumor (PNET), and rhabdomyosarcoma. Other differential diagnoses 
include squamous cell carcinoma and non-Hodgkin lymphoma. Accordingly, 
immunohistochemistry also plays an important role in the diagnosis. Human mel-
anoma black (HMB)-45 reaches the 100% specificity for melanoma, while Melan-A 
is slightly less specific (29–30). According to Morris et al., PNL-2 is a highly sensi-
tive marker for mucosal melanoma, superior to Melan-A and microphthalmia- 
associated transcription factor (MITF) and comparable with HMB-45 (29). 
Therefore, PNL-2 can be evaluated as an important adjunctive marker in the 
Figure 1 A rare histological image of a dermal, pleomorphic malignant melanocytic proliferation 
of the oral cavity, in a nonkeratinized epithelium. (Hematoxylin and Eosin, 20×) Courtesy of 
Dr. Angelina Pernazza.
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immunohistochemical evaluation of PMMs (26, 27). Furthermore, it is often dif-
ficult to distinguish a metastasis from a primary neoplasm. However, a de novo 
primary NPM is much more likely than a metastasis, although at the time of diag-
nosis, up to 50% of patients with primary NPM develop distant metastases to the 
brain, liver, and lungs (3). Therefore, after a diagnosis of an NPM, it is important 
to perform a general dermatological consultation, followed by a trachea-laryngoscopy, 
gastro-duodenoscopy, colonoscopy, and ophthalmological consultation, in order 
to exclude other localizations.
STAGING OF NPM
In order to study local tumor extension, the execution of computed tomography 
(CT) of facial bones and brain, as well as facial magnetic resonance imaging (MRI), 
is indicated. CT is performed with axial and coronal sections, 1–3 mm thick slices 
and dual window settings (for soft tissues and bone) (31).
MRI provides three sections: T1, T1 post-gadolinium, and T2. Usually, 
 melanomas exhibit a heterogeneous contrast enhancement with typical high 
and  low intensity signal on T1 and T2, respectively, related to high melanin 
Figure 2 This image demonstrates hyperplasia of the epidermis, an atypical dermal melanocytic 
proliferation, with several ectatic vessels and a lymphocytic infiltrate. Sometimes it is difficult to 
distinguish between a metastasis and a primary head and neck mucosal melanoma. 
(Hematoxylin and Eosin, 20×). Courtesy of Dr. Angelina Pernazza.
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concentration and/or bleeding within the mass. MRI also assesses bone infiltra-
tion and, eventually, brain metastases. While, total body CT and positron emis-
sion tomography (PET) remain the gold standards to detect systemic neoplastic 
involvement, all these investigations are necessary in order to guide appropriate 
management (31).
In 1970, the Ballantyne staging system for NPM was proposed, character-
ized by three stages, depending on disease extension: local, regional, or dissemi-
nated (31). Subsequently, in 2004, Prasad et al. proposed a splitting of stage I into 
three further stages, depending on the degree of the neoplastic invasion (Table 2) 
(32, 34–36). Another important and valid classification is the tumor–node– 
 metastasis (TNM) staging system of the seventh edition of the American Committee 
on Cancer (AJCC) (Table 2) (33). Due to the rarity of this malignancy, the  adequacy 
of these staging criteria for providing prognostic information is not clear. Further 
knowledge may allow for improvement of these staging schemas.
THERAPY
Surgical excision of NPM is considered the therapeutic gold standard (31). 
Performing external or intranasal incision depends on tumor site and size. It is 
difficult to control surgical margins both in case of endoscopic surgery and in case 
of an extranasal procedure. Intranasal surgery is usually performed for small 
intranasal masses. Tumor resection must provide 1.5–2 cm negative surgical mar-
gins, as defined by histological examination when NPM is ≥5 mm (31, 37). 
Craniofacial resection is indicated for neoplasms in contact with or infiltrating the 
skull base (37).
In cases of laryngeal or pharyngeal melanomas, complete neoplasm resec-
tion can be reached through total or partial laryngectomy or pharyngectomy 
(37). Unfortunately, it is important to note that these tumors can be aggressive 
and prone to recurrences, requiring extensive surgical resection and disfiguring 
surgery (31). In cases of oral cavity involvement, a radical surgical resection 
with tumor-free margins is the treatment of choice (5). However, in cases of 
large masses, a marginal or segmental mandibulectomy is needed, leading to 
disfigurement (5).
TABLE 2 Classifications of head and neck mucosal 
melanoma, including nasopharyngeal melanoma
Stage Ballantyne 1970 (31) Prasad 2004 (32) TNM 2009 (33)
I Any T0 N0 M0 Stage 1: in situ
Stage 2: invasion of 
lamina propria
Stage 3: deep tissue invasion
T3: epithelium/submucosa
T4a: deep soft tissue/cartilage/
bone
T4b: brain, dura, skull base
II Any T N M0
III Any T any N M1
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Sentinel lymph node biopsy is not usually performed for mucosal melanoma 
(31, 38). Lymph node dissection is indicated only in case of clinical and/or radio-
logical positivity (31, 38). Performing prophylactic lymph nodes dissection in the 
presence of clinical negativity is now under debate (31, 38). In addition, it should 
be remembered that regional recurrence is higher, above all, in melanomas with 
localization in the oral cavity (constituting 77% of recurrences) (20).
NPM is poorly radiosensitive; however, radiotherapy is indicated in cases of 
local recurrence, positive surgical margins, or in case of palliative therapy. Adjuvant 
radiotherapy seems to allow loco-regional control without any impact on survival 
(38). Indeed, no differences have been reported between patients treated with 
surgery alone and those with surgery and adjuvant radiotherapy (38). On the 
contrary, new radiotherapy techniques, like intensity-modulated radiation ther-
apy (IMRT), seem to be more effective and safe than the traditional ones, and are 
proposed as adjuvant therapy, regardless of surgical margins (6, 39). Head and 
neck stage III and IV a mucosal melanomas should be treated with a wide surgical 
resection and elective neck dissection, and eventually with adjuvant radiation 
therapy or IMRT (40).
Chemotherapy and/or immunotherapy are under evaluation. Anti-CTLA4, 
anti-PD1, anti-BRAF, and tyrosine-kinase inhibitors for the treatment of stage IV 
patients, however to date there is not any standardized procedure for manage-
ment. Furthermore, adverse reactions induced by these drugs should be carefully 
evaluated, because patients with nasal and NPM are generally elderly and comor-
bid (31). Indeed, NPM has a poor prognosis; specifically, melanomas of nasal 
cavity and paranasal sinus have a 5-year overall survival around 20–40% (41). 
Local recurrence is frequent, occurring in 50% of patients and commonly related 
to positive surgical margins (41). Age ≤50 years is associated with a better prog-
nosis compared with patients >50 years (41).
CONCLUSIONS
NPM is a rare HNMM with a poor prognosis and high rates of metastases and local 
recurrences. The poor prognosis is associated with a delay in the diagnosis, as well 
as with the intrinsic biology of the malignancy. Few studies have been reported in 
literature. An early diagnosis, correct staging, and correct therapy play a pivotal 
role in the management of this rare class of patients.
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